Valuing health technologies at nice: Recommendations for improved incorporation of treatment value in HTA

Health Economics

Volumn 19, Issue 10, 2010, Pages 1109-1116

  Goldman, Dana ^a   Lakdawalla, Darius ^a   Philipson, Tomas J ^b   Yin, Wesley ^c  

^a RAND CORPORATION   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

BIOMEDICAL TECHNOLOGY ASSESSMENT; CARDIOVASCULAR DISEASE; CAREGIVER BURDEN; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE SEVERITY; EDITORIAL; EMOTION; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE INDUSTRY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MEDICAL TECHNOLOGY; MENTAL DISEASE; NATIONAL HEALTH ORGANIZATION; PATIENT COMPLIANCE; PHYSICAL DISABILITY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; SCORING SYSTEM; SOCIAL ASPECT; SOCIAL WELFARE; TERMINALLY ILL PATIENT; UNITED KINGDOM;

CONSUMER SATISFACTION; COST-BENEFIT ANALYSIS; DIFFUSION OF INNOVATION; ECONOMICS, MEDICAL; EVALUATION STUDIES AS TOPIC; GREAT BRITAIN; HUMANS; PATIENT COMPLIANCE; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; STATE MEDICINE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 77957360238     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1654     Document Type: Editorial

References (36)

1. Barnett A. 2006. Insulin glargine in the treatment of type 1 and type 2 diabetes. Vascular Health Risk Management 2(1): 59-67.
2. Becker GS, Murphy KM, Philipson TJ. 2007. The Value of Life Near its End and Terminal Care. National Bureau of Economic Research.
3. Berndt E, Cockburn I, Grepin K. 2006. The impact of incremental innovation in biopharmaceuticals: drug utilization in original and supplemental indications. Pharmacoeonomics 24(Suppl 2): 69.
4. Boyle B, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW. 2008. Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression. HIV Clinical Trials 9(3): 164-176. (Pubitemid 351892870)
5. Christakis NA, Allison PD. 2009. Inter-spousal mortality effects: caregiver burden across the spectrum of disabling disease. In Health in Older Ages: The Causes and Consequences of Declining Disability Among the Elderly, Cutler D et al. (eds). University of Chicago Press: Chicago.
6. Devlin N, Parkin D. 1994. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics 13(2): 437-452.
7. Dickson M, Plauschinat CA. 2008. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. America Journal of Cardiovasccular Drugs 8(1): 45-50. (Pubitemid 351311519)
8. Dolan P, Cookson R, Ferguson B. 1999. Effect of discussion and deliberation on the public's views of priority setting in health care: focus group study. British Medical Journal 318: 916-919. (Pubitemid 29191929)
9. Dolan P, Edlin R, Tsuchiya A et al. 2008. The Relative Societal Value of Health Gains to Different Beneficiaries. Report to the NIHR and NICE.
10. Dolan P, Edlin R, Tsuchiya A, Wailoo A. 2007. It ain't what you do, it's the way that you do it: characteristics of procedural justice and their importance in social decision-making. Journal of Economic Behavior and Organization 64: 157-170.
11. Dolan P, Kahneman D. 2008. Interpretations of utility and their implications for the valuation of health. Economic Journal 118: 215-234.
12. Dolan P, Tsuchiya A. 2006. The elicitation of distributional judgements in the context of economic evaluation. In Companion to Health Economics, Jones A (ed.). Edward Elgar: Cheltenham.
13. Dolan P, Tsuchiya A, Williams A. 2003. NICE's citizen's council: what do we ask them, and how? The Lancet 362(9387): 918-919.
14. Dolan P, Tsuchiya A, Williams A. 2005. QALY maximisation and people's preferences: a methodological review of the literature. Health Economics 14: 197-208. (Pubitemid 40253634)
15. Drummond M, Wilson D, Kanavos P, Ubel P, Rovira J. 2007. Assessing the economic challenges posed by orphan drugs. International Journal of Technology Assessment in Health Care 23(1): 36-42. (Pubitemid 46648298)
16. Elwert F, Christakis NA. 2008. Variation in the effect of widowhood on mortality by the causes of death of both spouses. American Journal of Public Health 98(11): 2092-2098.
17. Food and Drug Administration. 2007. Review classification policy. Manual of Policies and Procedures, Center for Drug Evaluation and Research.
18. House of Representatives Subcommittee Report. 1982. Preliminary Report of the Survey on the Drugs for Rare Diseases. Subcommittee on the Health and the Environment, Government Printing Office, DC.
19. Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A, Mittmann N, Ilersich AL. 2002. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a metaanalysis. Clinical Therapeutics 24(2): 302-316. (Pubitemid 34208424)
20. Jena A, Philipson T. 2007. Cost-effectiveness as a price control. Health Affairs 26(3): 696-703.
21. Jena A, Philipson T. 2009. Endogenous cost-effectiveness analysis in health care technology adoption. NBER Working Paper.
22. Kennedy I. 2009. 'Appraising the value of innovation and other benefits, a short study for NICE' downloaded from: http://www.nice.org.uk/media/98F/5C/ KennedyStudyFinalReport.pdf on 20 June 2010.
23. Lichtenberg F, Waldfogel J. 2003. Does misery love company? Evidence from pharmaceutical markets before and after the Orphan Drug Act. NBER Working Paper No. 9750.
24. McCabe C, Claxton K, Tsuchiya A. 2005. Orphan drugs and the NHS: should we value rarity? British Medical Journal 331: 1016-1019.
25. National Institute for Health and Clinical Excellence. 2008. Appraising Life Extending, End of Life Treatments. Supplementary advice to the Appraisal Committees. NICE, London.
26. Nord E. 1993. The trade-off between severity of illness and treatment effect in cost-value analysis of health care. Health Policy 24: 227-238. (Pubitemid 23280732)
27. Nord E, Daniels N, Kamlet M. 2009. QALY's: some challenges. Value in Health 12: S10-S15.
28. Perry C. 2008. Does treating maternal depression improve child health management: the case of pediatric asthma. Journal of Health Economics 27(1): 157-173.
29. Pfeiffer PN, Ganoczy D, Valenstein M. 2008. Dosing frequency and adherence to antipsychotic medications. Psychiatr Service 59: 1207-1210.
30. Rice D, Fox P, Max W, Webber P et al. 1993. The economic burden of Alzheimer's disease care. Health Affairs 12(2): 164-176. (Pubitemid 23220072)
31. Ubel PA, Baron J, Nash B, Asch DA. 2000. Are preferences for equity over efficiency in health care allocation 'all or nothing'? Medical Care 38(4): 366-373.
32. Ubel PA, Loewenstein G. 1996. Distributing scarce livers: the moral reasoning of the general public. Social Science and Medicine 42: 1049-1055. (Pubitemid 26109024)
33. Wailoo A, Tsuchiya A, McCabe C. 2009. Weighting must wait: incorporating equity concerns into costeffectiveness analysis may take longer than expected. Pharmacoeconomics 27(12): 983-989.
34. Winfried K, Cometta A, de Bock R, Langenaeken J et al. 1999. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. New England Journal of Medicine 341(5): 312-318.
35. Yin W. 2008. Market incentives and pharmaceutical innovation. Journal of Health Economics 27(4): 1060-1077.
36. Zivin K, Christakis NA. 2007. The emotional toll of spousal morbidity and mortality. American Journal of Geriatric Psychiatry 15(9): 772-779.